Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanidatamab in Early Stage HER2+ Breast Cancer
NCT05035836Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2021
- Primary completion
- Dec 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zanidatamab in breast cancer, sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2021; status: recruiting.
02
Drugs
zanidatamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05035836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05035836.